Five marketing authorisations secured across four international markets
Venus Remedies has secured five marketing authorisations across four markets — Kazakhstan, Peru, Kuwait and Argentina.
By ScoutQuest · · 2 min read
- Marketing Authorisations Secured
- five marketing authorisations across four markets — Kazakhstan, Peru, Kuwait and Argentina
- Products and Markets
- Vancomycin and Fluorouracil (Kazakhstan), Fulvestrant (Peru), Methotrexate (Kuwait), Meropenem (Argentina)
- International Footprint
- over 100 countries
Venus Remedies Limited has informed the exchanges that it has secured five marketing authorisations across Kazakhstan, Peru, Kuwait and Argentina. A marketing authorisation is the permission a country's drug regulator gives before a medicine can be sold there — a product cannot be launched in that market without it.
What has been authorised
- Kazakhstan: Vancomycin and Fluorouracil
- Peru: Fulvestrant
- Kuwait: Methotrexate
- Argentina: Meropenem
Where these markets sit
- Kazakhstan is in the CIS region
- Peru and Argentina are in Latin America
- Kuwait is in the Middle East
The company states that the authorisations span markets across the CIS region, Latin America and the Middle East, strengthening its international presence and expanding access to its pharmaceutical portfolio across key global markets.
What the company said
- Saransh Chaudhary, Executive Director, Venus Remedies Ltd, and CEO, Venus Medicine Research Centre: the marketing authorisations mark another step in strengthening the company's international presence and expanding its product reach across diverse markets, and the company remains focused on building a strong global portfolio and making quality pharmaceutical solutions accessible to more patients worldwide.
- Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd: the international growth strategy is centred on expanding reach in high-potential markets while strengthening the product portfolio, and the company is committed to pursuing new opportunities through regulatory excellence, differentiated offerings and a sustained focus on global market expansion.
Scale already built
- The company describes itself as a leader in critical-care injectables.
- It says it has already established an international footprint in over 100 countries.
- It says it continues to focus on expanding its portfolio for exports across geographies and on building opportunities for sustainable international growth.
How to read this
- A marketing authorisation is a regulatory clearance to sell a specific product in a specific country. It is a step that comes before commercial supply in that market.
- This intimation names five authorisations and the products and countries they relate to, so an investor can map which molecules have been cleared for which market.
- The company frames the development as part of its wider international expansion effort, alongside an existing presence in over 100 countries.
In short, this is a regulatory-approval update covering four countries and five products across the CIS, Latin American and Middle Eastern markets.
Also from Venus Remedies
Social media posts on special window for re-lodgement of transfer requests of physical shares
14 Oct 2026
Board meeting on 26 October 2026 to consider and approve unaudited Q2 results
14 Oct 2026
Corporate Identification Number Changed After Object Clause Alteration
30 Sep 2026
More numbers
- Marketing authorisations securedfive
- International markets covered by the authorisationsfour
- Countries in the company's existing international footprintover 100
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.